Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 482 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Shelter Cat Who Battled Breast Cancer Seeks Fellow Survivor to Give... October 30, 2019 KRASG12D-Mutated NSCLC is Subtype with Distinct Co-mutations, a Colder Immune Microenvironment,... August 3, 2022 Similarity of Molecular Portraits in Synchronous Bilateral Breast Cancers Could be... March 22, 2023 Efficacy and Safety of FOLFIRI With Durvalumab With or Without Tremelimumab... April 22, 2024 Load more HOT NEWS Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in... Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality... Longer PFS in Patients with Advanced Melanoma Treated with TILs than... EMA Recommends Granting a Conditional Marketing Authorisation for Avapritinib
